SSG
GILD icon

Summit Securities Group’s Gilead Sciences GILD Stock Holding History

Summit Securities Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,432
Closed -$2.26M – 1180
2025
Q4 		$2.26M Buy
18,432
+12,530
+212% +$1.52M 0.29% 64
2025
Q3 		$655K Buy
+5,902
New +$671K 0.14% 144
2025
Q1 		– Sell
-21,897
Closed -$2.02M – 908
2024
Q4 		$2.02M Buy
21,897
+19,797
+943% +$1.78M 0.42% 47
2024
Q3 		$176K Buy
2,100
+135
+7% +$10.3K 0.05% 161
2024
Q2 		$135K Sell
1,965
-7,135
-78% -$476K 0.03% 194
2024
Q1 		$667K Buy
9,100
+5,100
+128% +$392K 0.11% 82
2023
Q4 		$324K Sell
4,000
-3,540
-47% -$275K 0.03% 218
2023
Q3 		$565K Buy
7,540
+1,317
+21% +$101K 0.06% 118
2023
Q2 		$480K Buy
6,223
+423
+7% +$33.7K 0.06% 147
2023
Q1 		$481K Sell
5,800
-65,100
-92% -$5.39M 0.04% 144
2022
Q4 		$6.09M Buy
70,900
+61,177
+629% +$4.84M 0.23% 71
2022
Q3 		$600K Sell
9,723
-777
-7% -$49K 0.04% 221
2022
Q2 		$649K Sell
10,500
-2,270
-18% -$141K 0.08% 166
2022
Q1 		$759K Sell
12,770
-74,544
-85% -$4.77M 0.08% 178
2021
Q4 		$6.34M Buy
87,314
+4,174
+5% +$287K 0.3% 67
2021
Q3 		$5.81M Buy
83,140
+29,761
+56% +$2.09M 0.45% 46
2021
Q2 		$3.68M Buy
53,379
+25,979
+95% +$1.73M 0.3% 72
2021
Q1 		$1.77M Sell
27,400
-30,400
-53% -$1.96M 0.19% 113
2020
Q4 		$3.37M Sell
57,800
-200
-0.3% -$12.1K 0.28% 97
2020
Q3 		$3.67M Buy
58,000
+17,000
+41% +$1.18M 0.38% 53
2020
Q2 		$3.15M Buy
41,000
+32,600
+388% +$2.5M 0.39% 56
2020
Q1 		$628K Sell
8,400
-11,000
-57% -$760K 0.11% 146
2019
Q4 		$1.26M Buy
19,400
+10,000
+106% +$651K 0.1% 185
2019
Q3 		$596K Sell
9,400
-2,500
-21% -$163K 0.05% 177
2019
Q2 		$804K Sell
11,900
-32,000
-73% -$2.11M 0.09% 158
2019
Q1 		$2.85M Buy
43,900
+17,400
+66% +$1.16M 0.52% 37
2018
Q4 		$1.66M Sell
26,500
-2,100
-7% -$147K 0.14% 97
2018
Q3 		$2.21M Buy
28,600
+14,200
+99% +$1.07M 0.82% 25
2018
Q2 		$1.02M Sell
14,400
-7,500
-34% -$530K 0.15% 83
2018
Q1 		$1.65M Buy
21,900
+14,200
+184% +$1.13M 0.4% 41
2017
Q4 		$552K Sell
7,700
-34,800
-82% -$2.64M 0.07% 91
2017
Q3 		$3.44M Buy
42,500
+36,700
+633% +$2.81M 0.59% 22
2017
Q2 		$411K Sell
5,800
-25,013
-81% -$1.66M 0.07% 132
2017
Q1 		$2.09M Sell
30,813
-26,882
-47% -$1.89M 0.6% 36
2016
Q4 		$4.13M Buy
+57,695
New +$4.29M 0.9% 22
2016
Q3 		– Sell
-16,650
Closed -$1.39M – 206
2016
Q2 		$1.39M Buy
+16,650
New +$1.48M 0.74% 31
2016
Q1 		– Sell
-62,300
Closed -$6.3M – 220
2015
Q4 		$6.3M Sell
62,300
-29,100
-32% -$3.03M 2.04% 12
2015
Q3 		$8.97M Sell
91,400
-53,000
-37% -$5.89M 6.47% 3
2015
Q2 		$16.9M Buy
144,400
+144,387
+1,110,669% +$15.8M 8.26% 3
2015
Q1 		$1K Sell
13
-22
-63% -$2.23K ﹤0.01% 350
2014
Q4 		$3K Buy
+35
New +$3.62K ﹤0.01% 516
2013
Q4 		– Sell
-100
Closed -$6K – 553
2013
Q3 		$6K Buy
+100
New +$5.98K ﹤0.01% 284

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Summit Securities Group's GILD Position: Q1 2026 in Review

Summit Securities Group sold out of Gilead Sciences (GILD) in Q1 2026, closing a stake of 18,432 shares — an estimated $2.26M sold.

Summit Securities Group first reported a position in GILD in Q3 2013 and held it in 42 quarters. The position peaked at $16.9M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Summit Securities Group reported no remaining Gilead Sciences position as of Q1 2026 after selling out during the quarter.
  • Summit Securities Group sold 18,432 Gilead Sciences shares in Q1 2026, an estimated $2.26M.
  • Summit Securities Group first reported a position in Gilead Sciences in Q3 2013 and held it in 42 quarters.
  • Summit Securities Group's Gilead Sciences position peaked at $16.9M in Q2 2015.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.